Login to Your Account

Deals And M&A NEWS

TAIPEI, Taiwan – Taiwan Liposome Co. (TLC) and Ablynx NV are planning to jointly develop a new drug delivery technology combining TLC's immunoliposome platform with Ablynx' antibody-derived nanobody technology that will enable more precisely targeted delivery of liposome-encapsulated cytotoxic compounds to disease sites in cancer patients.

Epirus Pharmaceuticals Inc.'s all-stock takeover of Zalicus Inc., disclosed on the same day that Epirus put the wraps on a $36 million series B round, will add early stage pain drug candidates to its pipeline of biosimilars and immediately put some joy back into Zalicus' shares.

SHANGHAI – 2013 was another banner year for biopharmaceutical licensing deals in China, with inbound agreements continuing to grow and outbound transactions showing up noticeably for the first time.
More Deals And M&A Headlines

Cast Your Vote

Has biotech’s bubble burst?: